ClinicalTrials.gg
Enrolling by invitationNCT07936981Updated Nov 13, 2026

Pain Assessment After Pediatric Indirect Inguinal Hernia Surgery

An interventional study of Joint analgesia in Postoperative Status and Inguinal Hernia in Children, sponsored by Xiangya Hospital of Central South University. Enrolling by invitation at 1 site in China. Open to participants aged Up to 14 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Xiangya Hospital of Central South University · Not applicable, Interventional, and Treatment

Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
Up to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies in Hernia, Inguinal with a site in China — 5 open to participants now, 5 under way, none of them phase 3. Hernia, Inguinal · China.

Planned enrollment
14th of 24
100 · median 117
Started
2026
with 1 other
No phase
20 of 27
5 open now
Registered
27th of 27
by date
Lead sponsor
2 of 27
Xiangya Hospital of Central South University

Among the 27 studies in Hernia, Inguinal with a site in China, this one is the 14th largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2026, is one of 20 with no phase, and was the 27th registered.

Hernia, Inguinal

545 studies on the registry are indexed under Hernia, Inguinal; 93 are open to participants now.

Browse Hernia, Inguinal studies →

Open to participants now

5 of the 27 studies in Hernia, Inguinal with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 56 Hernia, Inguinal studies recruiting now, 30 (54%) set no upper age limit and 17 (30%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: Up to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Hernia, Inguinal with a site in China, or all of them as a file.
02

Study summary

This experiment aims to compare the analgesic effects of two different and commonly used postoperative anesthesia methods on pediatric indirect inguinal hernia surgery, using two different pain scoring criteria, in order to identify the method with better analgesic effect and guide the selection of postoperative analgesia methods for pediatric indirect inguinal hernia surgery.

Read the detailed description

Detailed Description

  1. Study Background and Objectives

    Postoperative pain remains an important concern in children undergoing laparoscopic high ligation of the hernia sac for inguinal indirect hernia. Although this procedure is minimally invasive, incision-related pain and abdominal wall traction pain may affect children's postoperative comfort and recovery. The inguinal region has a rich nerve supply, and effective perioperative analgesia is therefore an important component of postoperative care in pediatric surgery.

    Local anesthetic wound infiltration is a relatively simple analgesic technique that can be performed directly at the surgical site without requiring an additional neuraxial procedure. Caudal analgesia is also commonly used in pediatric lower abdominal and inguinal surgery. However, comparative evidence regarding the potential benefits of combining these two approaches, compared with wound infiltration alone, remains limited in children undergoing laparoscopic inguinal hernia repair.

    This study aims to compare two ropivacaine-based analgesic strategies: incision-site local anesthetic infiltration alone and incision-site local anesthetic infiltration combined with caudal injection. The study is intended to provide clinical evidence regarding the relative benefits and limitations of these approaches and to inform the optimization of postoperative analgesia strategies in pediatric inguinal hernia surgery.

  2. Study Design and Setting

    This is a single-center, prospective, randomized controlled clinical study conducted at the Department of Pediatric Surgery, Xiangya Hospital, Central South University, China. The study plans to enroll 100 pediatric participants, who will be allocated in a 1:1 ratio to two analgesic groups.

    A stratified permuted-block randomization method will be used. The stratification factors are age group (0-3 years or 4-14 years) and hernia type (unilateral or bilateral), resulting in four randomization strata. The randomization sequence will be generated independently by a statistician who is not involved in participant screening or clinical treatment. Allocation concealment will be maintained using sequentially numbered, opaque, sealed envelopes within each stratum. The assigned intervention will be revealed after eligibility has been confirmed and the hernia type has been determined during surgery.

  3. Study Interventions

    All participants will undergo laparoscopic high ligation of the hernia sac. The principal difference between the two groups is the use or omission of an additional caudal injection.

    Group A: Incision-Site Local Anesthetic Infiltration Alone

    At the end of surgery and before wound closure, 0.2% ropivacaine will be administered by layered local infiltration around the inguinal surgical incision. The injection will cover the subcutaneous tissue and subcutaneous fascial layer around the operative wound. The total dose will be calculated according to the participant's body weight. No caudal injection will be performed in this group.

    Group B: Incision-Site Local Anesthetic Infiltration Combined with Caudal Injection

    Participants will receive the same incision-site infiltration with 0.2% ropivacaine as Group A. In addition, 0.2% ropivacaine will be administered by caudal injection at the end of surgery, before wound closure. The dose will be determined according to the participant's age and body weight in accordance with the study protocol.

  4. Standardization of Perioperative Management

    To ensure comparability between the groups, the surgical procedure, perioperative anesthesia management, postoperative monitoring, fluid management, and routine nursing care will follow standardized protocols. The use and dosage of perioperative opioids, nonsteroidal anti-inflammatory drugs, dexmedetomidine, and other relevant anesthetic or analgesic medications will be controlled according to the study protocol, with consistent weight-based dosing where applicable.

    The analgesic procedures will be performed by designated anesthesiologists to improve procedural consistency. Postoperative pain assessment procedures and the criteria and medications for rescue analgesia will also be standardized between the two groups. Any additional perioperative anesthetic or analgesic medications will be documented, including their names, doses, and administration times.

  5. Expected Significance

By comparing incision-site ropivacaine infiltration alone with the combination of incision-site infiltration and caudal ropivacaine injection, this study aims to clarify the potential additional analgesic benefit of caudal injection in children undergoing laparoscopic inguinal hernia repair. The findings may help inform the selection of appropriate regional analgesic techniques and support more standardized and individualized postoperative pain management in pediatric surgical practice.

03

Conditions studied

  • Postoperative Status
  • Inguinal Hernia in Children

Browse trials for

Keywords

  • postoperative status
  • Inguinal hernia in children
04

Who can participate

Ages eligible
Up to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Preoperative diagnosis of inguinal indirect hernia, without other pre-existing diseases as specified in the study protocol.
  2. Planned laparoscopic high ligation of the hernia sac at the Department of Pediatric Surgery, Xiangya Hospital.
  3. Age younger than 14 years, with no restriction on sex.
  4. No known allergy to anesthetic drugs.
  5. No significant postoperative complications that would prevent participation in the study, as specified in the protocol.

Exclusion criteria

Exclusion Criteria

  1. A history of allergy to anesthetic or analgesic drugs.
  2. to caudal block.
  3. Severe congenital cardiac structural abnormalities or hemodynamic abnormalities.
  4. Severe hepatic or renal dysfunction.
  5. Hypotension or bradycardia.
  6. Significant postoperative complications.
  7. Acidosis or hypoproteinemia.
  8. Other preoperative comorbid diseases specified in the study protocol.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • No intervention
    Subcutaneous analgesia group

    Incision-Site Local Anesthetic Infiltration Alone

  • Active comparator
    Joint analgesia group

    Incision-Site Local Anesthetic Infiltration Combined with Caudal Injection

    Behavioral: Joint analgesia

Interventions

  • BehavioralJoint analgesia

    Intraspinal injection of 0.2% ropivacaine, 1mg/kg+subcutaneous injection of 0.2% ropivacaine, 1mg/kg

06

What researchers measure

Primary outcomes

  1. FLACC Behavioral Pain Scale

    Postoperative pain in children aged 0-3 years will be assessed using the FLACC (Face, Legs, Activity, Cry, and Consolability) scale, an observational tool for children unable to reliably communicate pain. It evaluates five categories: (1) Face: relaxed, occasional grimacing, or persistent frowning; (2) Legs: relaxed, restless, or kicking; (3) Activity: lying quietly, squirming, or arching/rigidity; (4) Cry: no cry, moaning, or steady crying; and (5) Consolability: content, reassured by touch or talking, or difficult to console. Each category is scored 0-2, giving a total score of 0-10. A score of 0 indicates no observed pain, while 10 indicates the worst observed pain. Higher scores indicate more severe pain and a worse outcome. Assessments will be conducted at 2, 4, 6, 12, and 24 hours after the end of anesthesia. Scores will be recorded and compared between groups.

    Time frame: 2, 4, 6, 12, and 24 hours after the end of anesthesia.

  2. Numeric Rating Scale

    Postoperative pain intensity in children aged 4-14 years will be assessed using the Numeric Rating Scale (NRS), provided they can understand the scale and communicate their pain. Children will rate their current pain by selecting a number from 0 to 10. A score of 0 (minimum) indicates no pain, while 10 (maximum) indicates the worst possible pain. Scores from 1 to 9 represent progressively increasing pain intensity. The selected number reflects the child's perceived pain at each assessment. Higher scores indicate greater pain intensity, whereas lower scores indicate less pain. Assessments will be performed at 2, 4, 6, 12, and 24 hours after the end of anesthesia. Scores at each time point will be recorded and compared between the two treatment groups. The NRS will serve as the primary pain outcome measure for this age group.

    Time frame: 2, 4, 6, 12, and 24 hours after the end of anesthesia.

Secondary outcomes

  1. Incidence of Postoperative Adverse Reactions

    Adverse reactions associated with the anesthetic and analgesic interventions will be assessed in both groups. Participants will be monitored for vital signs and potential adverse reactions during the study. Events of particular interest include dizziness, nausea, vomiting, and shock. Other unexpected adverse events will also be documented, including their type and clinical manifestations. Serious adverse events, such as those requiring hospitalization, prolonged hospitalization, additional medical or surgical intervention, or resulting in death, will be recorded and reported. If an adverse reaction suspected to be related to the intervention occurs, the participant's clinical condition and vital signs will be assessed promptly, and appropriate supportive and symptomatic treatment will be provided. The incidence will be calculated as the proportion of participants experiencing at least one adverse reaction in each group and compared between groups.

    Time frame: From the end of anesthesia through 24 hours postoperatively.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Oct 2027, 12 months after the start.

Of 179 non-industry interventional studies with no phase under Hernia, Inguinal, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's planned 12 months is below that.

Counting every sponsor, half of 188 studies reached it within 19 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2026
First posted
Nov 13, 2026
StartActual
Oct 23, 2026
Primary completionEst.
Oct 30, 2027
CompletionEst.
Nov 15, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07936981
Responsible party
ZHU QIN (Doctor of Medicine, Xiangya Hospital of Central South University) — Principal investigator
First posted
Nov 13, 2026
Start date
Oct 23, 2026
Primary completion
Oct 30, 2027 (estimated)
Completion
Nov 15, 2027 (estimated)
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion